Podcasts

WFH Gene Therapy Registry

Presented by Barbara A. Konkle, MD and Johnny Mahlangu, BSc, MBBCh, MMed, FCPath

HTC Readiness: A Global Perspective

Presented by Steven W. Pipe, MD and Debra Pollard, RN

HTC Readiness: A Multidisciplinary Perspective

Presented by Steven W. Pipe, MD and Debra Pollard, RN

What Do Hemophilia Treatment Centers Need to Consider Now in Preparation for the Anticipated Availability of Gene Therapy?

Presented by Steven W. Pipe, MD and Nigel Key, MB, ChB. FRCP

Interpreting Vector Doses in Hemophilia Gene Therapy Clinical Trials

Presented by Steven W. Pipe, MD and Nigel Key, MB, ChB. FRCP

Hemophilia Gene Therapy in Patients With History of Inhibitors

Presented by Steven W. Pipe, MD and Nigel Key, MB, ChB. FRCP

Laboratory Measurement of Hemophilia Gene Therapy Products/Factor Activity

Presented by Steven W. Pipe, MD and Nigel Key, MB, ChB. FRCP

Adeno-Associated Virus (AAV) Mediated Gene Transfer: Why is This the Predominant Strategy for Hemophilia Gene Therapy?

Presented by Steven W. Pipe, MD and Nigel Key, MB, ChB. FRCP

Part 1: Pre-existing Immunity Against AAV Serotypes and What This Means for Hemophilia Gene Therapy Clinical Trials

Presented by Steven W. Pipe, MD and Nigel Key, MB, ChB. FRCP

Part 2: Pre-existing Immunity Against AAV Serotypes and What This Means for Hemophilia Gene Therapy Clinical Trials

Presented by Steven W. Pipe, MD and Nigel Key, MB, ChB. FRCP